
Please try another search
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
Name | Age | Since | Title |
---|---|---|---|
Carl H. June | 71 | 2020 | Chairman of Scientific Advisory Board |
Robert W. Postma | 71 | 2021 | Independent Director |
Holger Weis | 62 | 2020 | Chairman of the Board & CEO |
Kole Roybal | - | 2020 | Member of Scientific Advisory Board |
Jaime W. Vieser | 55 | 2020 | Independent Director |
Steven A. Feldman | - | - | Member of Scientific Advisory Board |
Michael A. Jerman | - | 2025 | Independent Director |
Matthew Porteus | 60 | 2020 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review